Phosphatidylcholine controlled release - Lipid Therapeutics
Alternative Names: LT-02; Phosphatidyl choline; Retarded release phosphatidylcholineLatest Information Update: 02 Jan 2023
At a glance
- Originator University of Heidelberg
- Developer Dr Falk Pharma; Lipid Therapeutics
- Class Antiulcers; Cytoprotectives; Glycerophospholipids; Lipids
- Mechanism of Action Mucoprotein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 02 Jan 2023 No development reported - Phase-III for Ulcerative colitis (Adjunctive treatment, Treatment-resistant) in Austria, Germany, Lithuania, Belgium, Netherlands, Hungary, Latvia, Poland, Slovakia (PO)
- 18 Sep 2020 No recent reports of development identified for phase-III for Ulcerative colitis (Adjunctive treatment, Treatment-resistant) in USA, Czech Republic and Netherlands (PO) (NCT02849951)
- 07 Feb 2017 Dr. Falk Pharma terminates a phase-III clinical trial due to IDMC recommendation in Ulcerative colitis (Treatment-resistant, Adjunctive treatment) in Austria, Belgium, the Czech Republic, Germany, Hungary, Latvia, Lithuania, Netherlands, Slovakia and Poland (PO) (NCT02142725)